



Nutrição sob a Ótica Teórica e Prática 2

Vanessa Bordin Viera
Natiéli Piovesan
(Organizadoras)

Atena
Editora
Ano 2021



Nutrição sob a Ótica Teórica e Prática 2

Vanessa Bordin Viera
Natiéli Piovesan
(Organizadoras)


Ano 2021

Editora Chefe

Profª Drª Antonella Carvalho de Oliveira

Assistentes Editoriais

Natalia Oliveira

Bruno Oliveira

Flávia Roberta Barão

Bibliotecária

Janaina Ramos

Projeto Gráfico e Diagramação

Natália Sandrini de Azevedo

Camila Alves de Cremo

Luiza Alves Batista

Maria Alice Pinheiro

Imagens da Capa

Shutterstock

Edição de Arte

Luiza Alves Batista

Revisão

Os Autores

2021 by Atena Editora

Copyright © Atena Editora

Copyright do Texto © 2021 Os autores

Copyright da Edição © 2021 Atena Editora

Direitos para esta edição cedidos à Atena Editora pelos autores.



Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição *Creative Commons*. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o *download* da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.

A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.

Conselho Editorial

Ciências Humanas e Sociais Aplicadas

Prof. Dr. Alexandre Jose Schumacher – Instituto Federal de Educação, Ciência e Tecnologia do Paraná

Prof. Dr. Américo Junior Nunes da Silva – Universidade do Estado da Bahia

Prof. Dr. Antonio Carlos Frasson – Universidade Tecnológica Federal do Paraná

Prof. Dr. Antonio Gasparetto Júnior – Instituto Federal do Sudeste de Minas Gerais
Prof. Dr. Antonio Isidro-Filho – Universidade de Brasília
Prof. Dr. Carlos Antonio de Souza Moraes – Universidade Federal Fluminense
Prof. Dr. Crisóstomo Lima do Nascimento – Universidade Federal Fluminense
Prof^ª Dr^ª Cristina Gaio – Universidade de Lisboa
Prof. Dr. Daniel Richard Sant’Ana – Universidade de Brasília
Prof. Dr. Deyvison de Lima Oliveira – Universidade Federal de Rondônia
Prof^ª Dr^ª Dilma Antunes Silva – Universidade Federal de São Paulo
Prof. Dr. Edvaldo Antunes de Farias – Universidade Estácio de Sá
Prof. Dr. Elson Ferreira Costa – Universidade do Estado do Pará
Prof. Dr. Eloi Martins Senhora – Universidade Federal de Roraima
Prof. Dr. Gustavo Henrique Cepolini Ferreira – Universidade Estadual de Montes Claros
Prof^ª Dr^ª Ivone Goulart Lopes – Instituto Internazionele delle Figlie de Maria Ausiliatrice
Prof. Dr. Jadson Correia de Oliveira – Universidade Católica do Salvador
Prof. Dr. Julio Candido de Meirelles Junior – Universidade Federal Fluminense
Prof^ª Dr^ª Lina Maria Gonçalves – Universidade Federal do Tocantins
Prof. Dr. Luis Ricardo Fernandes da Costa – Universidade Estadual de Montes Claros
Prof^ª Dr^ª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte
Prof. Dr. Marcelo Pereira da Silva – Pontifícia Universidade Católica de Campinas
Prof^ª Dr^ª Maria Luzia da Silva Santana – Universidade Federal de Mato Grosso do Sul
Prof^ª Dr^ª Paola Andressa Scortegagna – Universidade Estadual de Ponta Grossa
Prof^ª Dr^ª Rita de Cássia da Silva Oliveira – Universidade Estadual de Ponta Grossa
Prof. Dr. Rui Maia Diamantino – Universidade Salvador
Prof. Dr. Urandi João Rodrigues Junior – Universidade Federal do Oeste do Pará
Prof^ª Dr^ª Vanessa Bordin Viera – Universidade Federal de Campina Grande
Prof. Dr. William Cleber Domingues Silva – Universidade Federal Rural do Rio de Janeiro
Prof. Dr. Willian Douglas Guilherme – Universidade Federal do Tocantins

Ciências Agrárias e Multidisciplinar

Prof. Dr. Alexandre Igor Azevedo Pereira – Instituto Federal Goiano
Prof^ª Dr^ª Carla Cristina Bauermann Brasil – Universidade Federal de Santa Maria
Prof. Dr. Antonio Pasqualetto – Pontifícia Universidade Católica de Goiás
Prof. Dr. Cleberton Correia Santos – Universidade Federal da Grande Dourados
Prof^ª Dr^ª Daiane Garabeli Trojan – Universidade Norte do Paraná
Prof^ª Dr^ª Diocléa Almeida Seabra Silva – Universidade Federal Rural da Amazônia
Prof. Dr. Écio Souza Diniz – Universidade Federal de Viçosa
Prof. Dr. Fábio Steiner – Universidade Estadual de Mato Grosso do Sul
Prof. Dr. Fágner Cavalcante Patrocínio dos Santos – Universidade Federal do Ceará
Prof^ª Dr^ª Girlene Santos de Souza – Universidade Federal do Recôncavo da Bahia
Prof. Dr. Jael Soares Batista – Universidade Federal Rural do Semi-Árido
Prof. Dr. Júlio César Ribeiro – Universidade Federal Rural do Rio de Janeiro
Prof^ª Dr^ª Lina Raquel Santos Araújo – Universidade Estadual do Ceará
Prof. Dr. Pedro Manuel Villa – Universidade Federal de Viçosa
Prof^ª Dr^ª Raissa Rachel Salustriano da Silva Matos – Universidade Federal do Maranhão
Prof. Dr. Ronilson Freitas de Souza – Universidade do Estado do Pará
Prof^ª Dr^ª Talita de Santos Matos – Universidade Federal Rural do Rio de Janeiro
Prof. Dr. Tiago da Silva Teófilo – Universidade Federal Rural do Semi-Árido

Prof. Dr. Valdemar Antonio Paffaro Junior – Universidade Federal de Alfenas

Ciências Biológicas e da Saúde

Prof. Dr. André Ribeiro da Silva – Universidade de Brasília

Prof^ª Dr^ª Anelise Levay Murari – Universidade Federal de Pelotas

Prof. Dr. Benedito Rodrigues da Silva Neto – Universidade Federal de Goiás

Prof^ª Dr^ª Débora Luana Ribeiro Pessoa – Universidade Federal do Maranhão

Prof. Dr. Douglas Siqueira de Almeida Chaves – Universidade Federal Rural do Rio de Janeiro

Prof. Dr. Edson da Silva – Universidade Federal dos Vales do Jequitinhonha e Mucuri

Prof^ª Dr^ª Elizabeth Cordeiro Fernandes – Faculdade Integrada Medicina

Prof^ª Dr^ª Eleuza Rodrigues Machado – Faculdade Anhanguera de Brasília

Prof^ª Dr^ª Elane Schwinden Prudêncio – Universidade Federal de Santa Catarina

Prof^ª Dr^ª Eysler Gonçalves Maia Brasil – Universidade da Integração Internacional da Lusofonia Afro-Brasileira

Prof. Dr. Ferlando Lima Santos – Universidade Federal do Recôncavo da Bahia

Prof. Dr. Fernando Mendes – Instituto Politécnico de Coimbra – Escola Superior de Saúde de Coimbra

Prof^ª Dr^ª Gabriela Vieira do Amaral – Universidade de Vassouras

Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria

Prof. Dr. Helio Franklin Rodrigues de Almeida – Universidade Federal de Rondônia

Prof^ª Dr^ª Iara Lúcia Tescarollo – Universidade São Francisco

Prof. Dr. Igor Luiz Vieira de Lima Santos – Universidade Federal de Campina Grande

Prof. Dr. Jefferson Thiago Souza – Universidade Estadual do Ceará

Prof. Dr. Jesus Rodrigues Lemos – Universidade Federal do Piauí

Prof. Dr. Jônatas de França Barros – Universidade Federal do Rio Grande do Norte

Prof. Dr. José Max Barbosa de Oliveira Junior – Universidade Federal do Oeste do Pará

Prof. Dr. Luís Paulo Souza e Souza – Universidade Federal do Amazonas

Prof^ª Dr^ª Magnólia de Araújo Campos – Universidade Federal de Campina Grande

Prof. Dr. Marcus Fernando da Silva Praxedes – Universidade Federal do Recôncavo da Bahia

Prof^ª Dr^ª Maria Tatiane Gonçalves Sá – Universidade do Estado do Pará

Prof^ª Dr^ª Mylena Andréa Oliveira Torres – Universidade Ceuma

Prof^ª Dr^ª Natiéli Piovesan – Instituto Federaci do Rio Grande do Norte

Prof. Dr. Paulo Inada – Universidade Estadual de Maringá

Prof. Dr. Rafael Henrique Silva – Hospital Universitário da Universidade Federal da Grande Dourados

Prof^ª Dr^ª Regiane Luz Carvalho – Centro Universitário das Faculdades Associadas de Ensino

Prof^ª Dr^ª Renata Mendes de Freitas – Universidade Federal de Juiz de Fora

Prof^ª Dr^ª Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa

Prof^ª Dr^ª Vanessa Bordin Viera – Universidade Federal de Campina Grande

Ciências Exatas e da Terra e Engenharias

Prof. Dr. Adélio Alcino Sampaio Castro Machado – Universidade do Porto

Prof. Dr. Carlos Eduardo Sanches de Andrade – Universidade Federal de Goiás

Prof^ª Dr^ª Carmen Lúcia Voigt – Universidade Norte do Paraná

Prof. Dr. Cleiseano Emanuel da Silva Paniagua – Instituto Federal de Educação, Ciência e Tecnologia de Goiás

Prof. Dr. Douglas Gonçalves da Silva – Universidade Estadual do Sudoeste da Bahia

Prof. Dr. Eloi Rufato Junior – Universidade Tecnológica Federal do Paraná
Prof^ª Dr^ª Érica de Melo Azevedo – Instituto Federal do Rio de Janeiro
Prof. Dr. Fabrício Menezes Ramos – Instituto Federal do Pará
Prof^ª Dra. Jéssica Verger Nardeli – Universidade Estadual Paulista Júlio de Mesquita Filho
Prof. Dr. Juliano Carlo Rufino de Freitas – Universidade Federal de Campina Grande
Prof^ª Dr^ª Luciana do Nascimento Mendes – Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Norte
Prof. Dr. Marcelo Marques – Universidade Estadual de Maringá
Prof. Dr. Marco Aurélio Kistemann Junior – Universidade Federal de Juiz de Fora
Prof^ª Dr^ª Neiva Maria de Almeida – Universidade Federal da Paraíba
Prof^ª Dr^ª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte
Prof^ª Dr^ª Priscila Tessmer Scaglioni – Universidade Federal de Pelotas
Prof. Dr. Takeshy Tachizawa – Faculdade de Campo Limpo Paulista

Linguística, Letras e Artes

Prof^ª Dr^ª Adriana Demite Stephani – Universidade Federal do Tocantins
Prof^ª Dr^ª Angeli Rose do Nascimento – Universidade Federal do Estado do Rio de Janeiro
Prof^ª Dr^ª Carolina Fernandes da Silva Mandaji – Universidade Tecnológica Federal do Paraná
Prof^ª Dr^ª Denise Rocha – Universidade Federal do Ceará
Prof. Dr. Fabiano Tadeu Grazioli – Universidade Regional Integrada do Alto Uruguai e das Missões
Prof. Dr. Gilmei Fleck – Universidade Estadual do Oeste do Paraná
Prof^ª Dr^ª Keyla Christina Almeida Portela – Instituto Federal de Educação, Ciência e Tecnologia do Paraná
Prof^ª Dr^ª Miranilde Oliveira Neves – Instituto de Educação, Ciência e Tecnologia do Pará
Prof^ª Dr^ª Sandra Regina Gardacho Pietrobon – Universidade Estadual do Centro-Oeste
Prof^ª Dr^ª Sheila Marta Carregosa Rocha – Universidade do Estado da Bahia

Conselho Técnico Científico

Prof. Me. Abrãao Carvalho Nogueira – Universidade Federal do Espírito Santo
Prof. Me. Adalberto Zorzo – Centro Estadual de Educação Tecnológica Paula Souza
Prof. Dr. Adaylson Wagner Sousa de Vasconcelos – Ordem dos Advogados do Brasil/Seccional Paraíba
Prof. Dr. Adilson Tadeu Basquerote Silva – Universidade para o Desenvolvimento do Alto Vale do Itajaí
Prof. Dr. Alex Luis dos Santos – Universidade Federal de Minas Gerais
Prof. Me. Alexandro Teixeira Ribeiro – Centro Universitário Internacional
Prof^ª Ma. Aline Ferreira Antunes – Universidade Federal de Goiás
Prof. Me. André Flávio Gonçalves Silva – Universidade Federal do Maranhão
Prof^ª Ma. Andréa Cristina Marques de Araújo – Universidade Fernando Pessoa
Prof^ª Dr^ª Andreza Lopes – Instituto de Pesquisa e Desenvolvimento Acadêmico
Prof^ª Dr^ª Andrezza Miguel da Silva – Faculdade da Amazônia
Prof^ª Ma. Anelisa Mota Gregoleti – Universidade Estadual de Maringá
Prof^ª Ma. Anne Karynne da Silva Barbosa – Universidade Federal do Maranhão
Prof. Dr. Antonio Hot Pereira de Faria – Polícia Militar de Minas Gerais
Prof. Me. Armando Dias Duarte – Universidade Federal de Pernambuco
Prof^ª Ma. Bianca Camargo Martins – UniCesumar

Profª Ma. Carolina Shimomura Nanya – Universidade Federal de São Carlos
Prof. Me. Carlos Antônio dos Santos – Universidade Federal Rural do Rio de Janeiro
Prof. Me. Christopher Smith Bignardi Neves – Universidade Federal do Paraná
Prof. Ma. Cláudia de Araújo Marques – Faculdade de Música do Espírito Santo
Profª Drª Cláudia Taís Siqueira Cagliari – Centro Universitário Dinâmica das Cataratas
Prof. Me. Clécio Danilo Dias da Silva – Universidade Federal do Rio Grande do Norte
Prof. Me. Daniel da Silva Miranda – Universidade Federal do Pará
Profª Ma. Daniela da Silva Rodrigues – Universidade de Brasília
Profª Ma. Daniela Remião de Macedo – Universidade de Lisboa
Profª Ma. Dayane de Melo Barros – Universidade Federal de Pernambuco
Prof. Me. Douglas Santos Mezacas – Universidade Estadual de Goiás
Prof. Me. Edevaldo de Castro Monteiro – Embrapa Agrobiologia
Prof. Me. Eduardo Gomes de Oliveira – Faculdades Unificadas Doctum de Cataguases
Prof. Me. Eduardo Henrique Ferreira – Faculdade Pitágoras de Londrina
Prof. Dr. Edwaldo Costa – Marinha do Brasil
Prof. Me. Eliel Constantino da Silva – Universidade Estadual Paulista Júlio de Mesquita
Prof. Me. Ernane Rosa Martins – Instituto Federal de Educação, Ciência e Tecnologia de Goiás
Prof. Me. Euvaldo de Sousa Costa Junior – Prefeitura Municipal de São João do Piauí
Prof. Dr. Everaldo dos Santos Mendes – Instituto Edith Theresa Hedwing Stein
Prof. Me. Ezequiel Martins Ferreira – Universidade Federal de Goiás
Profª Ma. Fabiana Coelho Couto Rocha Corrêa – Centro Universitário Estácio Juiz de Fora
Prof. Me. Fabiano Eloy Atilio Batista – Universidade Federal de Viçosa
Prof. Me. Felipe da Costa Negrão – Universidade Federal do Amazonas
Prof. Me. Francisco Odécio Sales – Instituto Federal do Ceará
Profª Drª Germana Ponce de Leon Ramírez – Centro Universitário Adventista de São Paulo
Prof. Me. Gevair Campos – Instituto Mineiro de Agropecuária
Prof. Me. Givanildo de Oliveira Santos – Secretaria da Educação de Goiás
Prof. Dr. Guilherme Renato Gomes – Universidade Norte do Paraná
Prof. Me. Gustavo Krahl – Universidade do Oeste de Santa Catarina
Prof. Me. Helton Rangel Coutinho Junior – Tribunal de Justiça do Estado do Rio de Janeiro
Profª Ma. Isabelle Cerqueira Sousa – Universidade de Fortaleza
Profª Ma. Jaqueline Oliveira Rezende – Universidade Federal de Uberlândia
Prof. Me. Javier Antonio Albornoz – University of Miami and Miami Dade College
Prof. Me. Jhonatan da Silva Lima – Universidade Federal do Pará
Prof. Dr. José Carlos da Silva Mendes – Instituto de Psicologia Cognitiva, Desenvolvimento Humano e Social
Prof. Me. Jose Elyton Batista dos Santos – Universidade Federal de Sergipe
Prof. Me. José Luiz Leonardo de Araujo Pimenta – Instituto Nacional de Investigación Agropecuaria Uruguay
Prof. Me. José Messias Ribeiro Júnior – Instituto Federal de Educação Tecnológica de Pernambuco
Profª Drª Juliana Santana de Curcio – Universidade Federal de Goiás
Profª Ma. Juliana Thaisa Rodrigues Pacheco – Universidade Estadual de Ponta Grossa
Profª Drª Kamilly Souza do Vale – Núcleo de Pesquisas Fenomenológicas/UFPA
Prof. Dr. Kárpio Márcio de Siqueira – Universidade do Estado da Bahia
Profª Drª Karina de Araújo Dias – Prefeitura Municipal de Florianópolis
Prof. Dr. Lázaro Castro Silva Nascimento – Laboratório de Fenomenologia & Subjetividade/UFPR

Prof. Me. Leonardo Tullio – Universidade Estadual de Ponta Grossa
Prof^ª Ma. Lillian Coelho de Freitas – Instituto Federal do Pará
Prof^ª Ma. Liliansi Aparecida Sereno Fontes de Medeiros – Consórcio CEDERJ
Prof^ª Dr^ª Lívia do Carmo Silva – Universidade Federal de Goiás
Prof. Dr. Lucio Marques Vieira Souza – Secretaria de Estado da Educação, do Esporte e da Cultura de Sergipe
Prof. Dr. Luan Vinicius Bernardelli – Universidade Estadual do Paraná
Prof^ª Ma. Luana Ferreira dos Santos – Universidade Estadual de Santa Cruz
Prof^ª Ma. Luana Vieira Toledo – Universidade Federal de Viçosa
Prof. Me. Luis Henrique Almeida Castro – Universidade Federal da Grande Dourados
Prof^ª Ma. Luma Sarai de Oliveira – Universidade Estadual de Campinas
Prof. Dr. Michel da Costa – Universidade Metropolitana de Santos
Prof. Me. Marcelo da Fonseca Ferreira da Silva – Governo do Estado do Espírito Santo
Prof. Dr. Marcelo Máximo Purificação – Fundação Integrada Municipal de Ensino Superior
Prof. Me. Marcos Aurelio Alves e Silva – Instituto Federal de Educação, Ciência e Tecnologia de São Paulo
Prof^ª Ma. Maria Elanny Damasceno Silva – Universidade Federal do Ceará
Prof^ª Ma. Marileila Marques Toledo – Universidade Federal dos Vales do Jequitinhonha e Mucuri
Prof. Me. Pedro Panhoca da Silva – Universidade Presbiteriana Mackenzie
Prof^ª Dr^ª Poliana Arruda Fajardo – Universidade Federal de São Carlos
Prof. Me. Ricardo Sérgio da Silva – Universidade Federal de Pernambuco
Prof. Me. Renato Faria da Gama – Instituto Gama – Medicina Personalizada e Integrativa
Prof^ª Ma. Renata Luciane Polsaque Young Blood – UniSecal
Prof. Me. Robson Lucas Soares da Silva – Universidade Federal da Paraíba
Prof. Me. Sebastião André Barbosa Junior – Universidade Federal Rural de Pernambuco
Prof^ª Ma. Silene Ribeiro Miranda Barbosa – Consultoria Brasileira de Ensino, Pesquisa e Extensão
Prof^ª Ma. Solange Aparecida de Souza Monteiro – Instituto Federal de São Paulo
Prof^ª Ma. Taiane Aparecida Ribeiro Nepomoceno – Universidade Estadual do Oeste do Paraná
Prof. Me. Tallys Newton Fernandes de Matos – Faculdade Regional Jaguaribana
Prof^ª Ma. Thatianny Jasmine Castro Martins de Carvalho – Universidade Federal do Piauí
Prof. Me. Tiago Silvio Dedoné – Colégio ECEL Positivo
Prof. Dr. Welleson Feitosa Gazel – Universidade Paulista

Nutrição sob a ótica teórica e prática 2

Editora Chefe: Profª Drª Antonella Carvalho de Oliveira
Bibliotecária: Janaina Ramos
Diagramação: Camila Alves de Cremona
Correção: Giovanna Sandrini de Azevedo
Edição de Arte: Luiza Alves Batista
Revisão: Os Autores
Organizadores: Vanessa Bordin Viera
Natiéli Piovesan

Dados Internacionais de Catalogação na Publicação (CIP)

N976 Nutrição sob a ótica teórica e prática 2 / Organizadoras
Vanessa Bordin Viera, Natiéli Piovesan. – Ponta Grossa
- PR: Atena, 2021.

Formato: PDF

Requisitos de sistema: Adobe Acrobat Reader

Modo de acesso: World Wide Web

Inclui bibliografia

ISBN 978-65-5706-951-6

DOI 10.22533/at.ed.516210104

1. Nutrição. 2. Pesquisa. I. Viera, Vanessa Bordin
(Organizadora). II. Piovesan, Natiéli (Organizadora). III. Título.
CDD 613

Elaborado por Bibliotecária Janaina Ramos – CRB-8/9166

Atena Editora

Ponta Grossa – Paraná – Brasil

Telefone: +55 (42) 3323-5493

www.atenaeditora.com.br

contato@atenaeditora.com.br

DECLARAÇÃO DOS AUTORES

Os autores desta obra: 1. Atestam não possuir qualquer interesse comercial que constitua um conflito de interesses em relação ao artigo científico publicado; 2. Declaram que participaram ativamente da construção dos respectivos manuscritos, preferencialmente na: a) Concepção do estudo, e/ou aquisição de dados, e/ou análise e interpretação de dados; b) Elaboração do artigo ou revisão com vistas a tornar o material intelectualmente relevante; c) Aprovação final do manuscrito para submissão.; 3. Certificam que os artigos científicos publicados estão completamente isentos de dados e/ou resultados fraudulentos; 4. Confirmam a citação e a referência correta de todos os dados e de interpretações de dados de outras pesquisas; 5. Reconhecem terem informado todas as fontes de financiamento recebidas para a consecução da pesquisa.

APRESENTAÇÃO

O *e-book* “Nutrição sob a Ótica Teórica e Prática 2” traz 20 artigos científicos com temáticas atuais como alimentos biofortificados, análises de composição nutricional de cardápios, gordura trans, hábitos alimentares; dietas da moda, transtornos alimentares; aleitamento materno; vitamina D, alimentação saudável, entre outros assuntos que envolvem diversas áreas da nutrição.

Convidamos todos para uma leitura visando obter conhecimento e promover reflexões sobre os temas deste *e-book*.

Vanessa Bordin Viera
Natiéli Piovesan

SUMÁRIO

CAPÍTULO 1..... 1

ADOÇÃO DE ALIMENTOS BIOFORTIFICADOS COMO ESTRATÉGIA PARA SUPRIR AS DEFICIÊNCIAS DE MICRONUTRIENTES NA ALIMENTAÇÃO ESCOLAR

Alinne Oliveira Nunes Azevedo

Fabiola Teixeira Azevedo

Clara dos Reis Nunes

DOI 10.22533/at.ed.5162101041

CAPÍTULO 2..... 16

ANÁLISE DA COMPOSIÇÃO NUTRICIONAL DE CARDÁPIOS DISPONIBILIZADOS POR BLOGUEIRAS EM SITES DA INTERNET

Vanessa Barros de Carvalho

Maria Luiza Maranhão Fonseca

Cleudiane de Jesus Louredo Pereira

Samara dos Santos Feitosa

Silvio Carvalho Marinho

Jethania Glasses Cutrim Furtado Ferreira

Karyne Antonia de Sousa Figueredo

Marcos Roberto Campos de Macedo

DOI 10.22533/at.ed.5162101042

CAPÍTULO 3..... 27

ARROZES ESPECIAIS: INCENTIVO A CRIAÇÕES GASTRONÔMICAS

Mariluce Luglio Kosugi

DOI 10.22533/at.ed.5162101043

CAPÍTULO 4..... 34

AUXILIO DA NUTRIÇÃO NO TRATAMENTO DA ESCLEROSE LATERAL AMIOTRÓFICA

Amanda Diely Brito Bulhões da Silva

Alexandre Augusto Pinheiro de Oliveira

Giulianna Campos Lamas

Juliana Carolina Pantoja Revorêdo

DOI 10.22533/at.ed.5162101044

CAPÍTULO 5..... 43

CONSUMO DE ALIMENTOS ULTRAPROCESSADOS FONTES DE GORDURA TRANS

Marcela Brito Parente

Karla Cavalcante Quadros

Hugo Rangel Fernandes

DOI 10.22533/at.ed.5162101045

CAPÍTULO 6..... 58

DESENVOLVIMENTO E CARACTERIZAÇÃO DE BISCOITO FUNCIONAL PRODUZIDO COM RESÍDUOS DA INDUSTRIALIZAÇÃO DA UVA

Marvi Paola Sommer da Silva

Rosselei Caiel da Silva
Rochele Cassanta Rossi
Ingrid Duarte dos Santos

DOI 10.22533/at.ed.5162101046

CAPÍTULO 7..... 66

EFFICACY OF SUPPLEMENTATION WITH MYO-INOSITOL IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME - META-ANALYSIS

Paula Porto Machado de Paula
Lucas Cândido Gonçalves
Paulo Alex Neves da Silva
Antonio Márcio Teodoro Cordeiro Silva
Xisto Sena Passos
Natália Menezes Silva

DOI 10.22533/at.ed.5162101047

CAPÍTULO 8..... 82

FATOR DE CORREÇÃO DE HORTALIÇAS EM SERVIÇOS DE ALIMENTAÇÃO: INDICADOR DE BOAS PRÁTICAS E SUSTENTABILIDADE

Suzana Felix dos Santos
Priscila Guadagno de Souza
Talita Braga de Brito Nogueira
Ana Elizabeth Cavalcante Fai

DOI 10.22533/at.ed.5162101048

CAPÍTULO 9..... 97

FERRAMENTAS DE GERENCIAMENTO PARA O CONTROLE DE CUSTOS EM UNIDADES PRODUTORAS DE REFEIÇÕES (UPRs)

Candice de Oliveira Aires Sousa
Teresa Elisa Sousa da Silva
Grazielle Louise Ribeiro de Oliveira

DOI 10.22533/at.ed.5162101049

CAPÍTULO 10..... 116

HÁBITOS ALIMENTARES APRESENTADOS POR ESTUDANTES DE UMA ESCOLA PRIVADA DE MACEIÓ/AL

Deborah Maria Tenório Braga Cavalcante Pinto
Karen Bastos de Amorim
Pedro de Medeiros Monteiro
Fabiana Palmeira Melo Costa
Vinícius Tenório Braga Cavalcante Pinto
Letícia Aldeman de Oliveira Rodrigues
Eduarda de Almeida Paz Costa

DOI 10.22533/at.ed.51621010410

CAPÍTULO 11..... 124

INOVAÇÃO EM NUTRIÇÃO ESPORTIVA

Anna Claudia Sahade Brunatti Abrão

Pedro Henrique Silva de Rossi

DOI 10.22533/at.ed.51621010411

CAPÍTULO 12..... 132

IMPACTOS DA UTILIZAÇÃO DE DIETAS DA MODA NA SAÚDE DE INDIVÍDUOS EXCESSO DE PESO E OBESOS: UMA REVISÃO DE LITERATURA

Brenda Pontes do Nascimento

Hercília Oliveira Santos

Sandra Machado Lira

Carla Laine Silva Lima

Marcelo Oliveira Holanda

Paula Alves salmito

Fernando Cesar Rodrigues Brito

Natalia do Vale Canabrava

Chayane Gomes Marques

José Ytalo Gomes da Silva

Bruno Bezerra da Silva

Raquel Teixeira Terceiro Paim

DOI 10.22533/at.ed.51621010412

CAPÍTULO 13..... 142

INSEGURANÇA ALIMENTAR EM MULHERES GESTANTES E NÃO GESTANTES

Flávia Maiele Pedroza Trajano

Rafaela Lira Formiga Cavalcanti de Lima

Maria Augusta Correa Barroso Magno Viana

Maria do Carmo Pedroza Trajano

Nadjeanny Ingrid Galdino Gomes

João Agnaldo do Nascimento

Rodrigo Pinheiro de Toledo Vianna

DOI 10.22533/at.ed.51621010413

CAPÍTULO 14..... 155

VIVÊNCIA DE ACADÊMICA DE NUTRIÇÃO EM BANCO DE LEITE HUMANO: RELATO DE EXPERIÊNCIA

Gabrielle Tomaz Nunes

Grace Kelly Pestana dos Santos

Roseli Correia

Elizabete Helbig

DOI 10.22533/at.ed.51621010414

CAPÍTULO 15..... 166

OS MÉTODOS DE INTRODUÇÃO ALIMENTAR CONVENCIONAL E BABY-LED WEANING (BLW): UMA REVISÃO INTEGRATIVA DE LITERATURA

Amanda Diely Brito Bulhões da Silva

Alexandre Augusto Pinheiro de Oliveira

Giuliana Campos Lamas

Juliana Carolina Pantoja Revorêdo

DOI 10.22533/at.ed.51621010415

CAPÍTULO 16..... 177

OS PRIMEIROS MIL DIAS DA CRIANÇA: UMA JANELA DE OPORTUNIDADES À PROMOÇÃO DA ALIMENTAÇÃO SAUDÁVEL

Aline Prado dos Santos
Sarah Camila Fortes Santos
Leidiany Ramos Brito Silva

DOI 10.22533/at.ed.51621010416

CAPÍTULO 17..... 182

PERCEÇÃO DA AUTOIMAGEM E RISCO DE TRANSTORNOS ALIMENTARES EM ESTUDANTES DE NUTRIÇÃO

Renata Castelo Aguiar
Rodrigo Holanda Torrel
Sandra Machado Lira
Carla Laine Silva Lima
Marcelo Oliveira Holanda
Paula Alves salmito
Fernando Cesar Rodrigues Brito
Natalia do Vale Canabrava
Chayane Gomes Marques
José Ytalo Gomes da Silva
Bruno Bezerra da Silva
Raquel Teixeira Terceiro Paim

DOI 10.22533/at.ed.51621010417

CAPÍTULO 18..... 194

PERCEÇÃO SOBRE A DIETA HOSPITALAR, MITOS E VERDADES SOBRE A ALIMENTAÇÃO DURANTE A GESTAÇÃO: RELATO DE ATIVIDADES ACADÊMICAS DE EXTENSÃO NO HU/FURG

Gabrielle Tomaz Nunes
Grace Kelly Pestana dos Santos
Roseli Correia
Elizabete Helbig

DOI 10.22533/at.ed.51621010418

CAPÍTULO 19..... 202

PERFIL DO ALEITAMENTO MATERNO E MORBIDADE POR DIARREIA EM CRIANÇAS COM ATÉ SEIS MESES DE VIDA

Leila Magda Rodrigues Almeida
Djanilson Barbosa Santos
Gisele Queiroz Carvalho

DOI 10.22533/at.ed.51621010419

CAPÍTULO 20..... 214

PREVALÊNCIA DA INSUFICIÊNCIA/DEFICIÊNCIA DA VITAMINA D E SUA ASSOCIAÇÃO COM EXPOSIÇÃO SOLAR E CONSUMO ALIMENTAR DE VITAMINA D E CÁLCIO EM PORTADORES DE FIBROSE CÍSTICA

Élida Felinto dos Prazeres

Raiane Fernandes de Azevedo Cruz
Maria Paula de Paiva
Dayanna Joyce Marques Queiroz
Celso Costa da Silva Júnior
Maria da Conceição Rodrigues Gonçalves

DOI 10.22533/at.ed.51621010420

CAPÍTULO 21.....227

I FEIRA DE SAÚDE E EDUCAÇÃO “ALIMENTAÇÃO SAUDÁVEL E VIDA”: CONSTRUINDO CAMINHOS PARA O CUIDADO

Kellen da Costa Barbosa
Aline Cristiane da Costa Dias
Georgette do Socorro Negrão Macedo
Alan Machado de Almeida

DOI 10.22533/at.ed.51621010421

SOBRE AS ORGANIZADORAS.....235

ÍNDICE REMISSIVO.....236

EFFICACY OF SUPPLEMENTATION WITH MYO-INOSITOL IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME - META-ANALYSIS

Data de aceite: 29/03/2021

Data de submissão: 04/01/2021

Paula Porto Machado de Paula

Universidade Paulista – UNIP
Goiânia – GO
<https://orcid.org/0000-0001-9625-6390>

Lucas Cândido Gonçalves

Universidade Federal de Goiás - UFG
Goiânia – GO
<https://orcid.org/0000-0001-7246-9359>

Paulo Alex Neves da Silva

Universidade Federal de Goiás - UFG
Goiânia – GO
<https://orcid.org/0000-0002-0675-9873>

Antonio Márcio Teodoro Cordeiro Silva

Pontifícia Universidade Católica – PUC
Goiânia – GO
<https://orcid.org/0000-0003-0645-3599>

Xisto Sena Passos

Universidade Paulista – UNIP
Goiânia – GO
<https://orcid.org/0000-0001-5718-5323>

Natália Menezes Silva

Universidade Paulista – UNIP
Goiânia – GO
<https://orcid.org/0000-0003-0445-2584>

ABSTRACT: Objective- Statistically analyze the hypothesis that the efficacy of interventions with myo-inositol, in polycystic ovary syndrome,

is superior or similar to metformin, considering, as comparative parameters, the index of the model for the evaluation of homeostasis, serum glucose, insulin, luteinizing hormone and follicle stimulating hormone. **Methods-** This is a meta-analysis, according to the PRISMA protocol. Twelve articles were select from the databases for data extraction. Subsequently, the mean difference test was perform for continuous data. The tests were performed with the STATA® 16.0 software, considering the significance limit of 5% ($p=0.05$). **Results-** The effectiveness of metformin related was to the highest concentration (2,550 mg), on the other hand, all interventions, with myo-inositol, showed significant results, with emphasis on the intervention with 2 g of myo-inositol associated with 200 μg of folic acid, which was efficient in the control of luteinizing hormone and follicle stimulating hormone. Thus, considering 2 g of myo-inositol associated with 200 μg of folic acid, the differences between means were: for the index of the homeostasis assessment model, MD= 1.4 ($p=0.00$); for insulin, MD= 5.9 ($p=0.00$); for follicle stimulating hormone, MD= 2.5 ($p=0.00$); and for luteinizing hormone, MD= 4.9 ($p=0.00$). The intervention using 4 g of myo-inositol, with 400 μg of folic acid, showed a reduction in the serum glucose level, with MD= 6.2 ($p=0.00$). **Conclusion-** The results of this meta-analysis point to myo-inositol as a treatment option for polycystic ovary syndrome, considering the absence of side effects and the efficacy similar or superior to metformin.

KEYWORDS: Myo-Inositol, Metformin, Polycystic Ovary Syndrome.

EFICÁCIA DA SUPLEMENTAÇÃO COM MIO-INOSITOL NO TRATAMENTO DA SÍNDROME DO OVÁRIO POLICÍSTICO - METANÁLISE

RESUMO: Objetivo- Analisar estatisticamente a hipótese de que a eficácia das intervenções com mio-inositol, na síndrome do ovário policístico, é superior ou semelhante à metformina, considerando, como parâmetros comparativos, o índice do modelo para avaliação da homeostase, glicose sérica, insulina, hormônio luteinizante e hormônio folículo estimulante.

Método- Trata-se de uma meta-análise de acordo com o protocolo PRISMA. Doze artigos foram selecionados das bases de dados para extração de dados. Posteriormente, foi realizado o teste de diferença entre médias para dados contínuos. Os testes foram realizados no software STATA® 16.0, considerando o limite de significância de 5% ($p = 0,05$). **Resultados-** A eficácia da metformina foi relacionada à maior concentração (2.550 mg), por outro lado, todas as intervenções, com mio-inositol, apresentaram resultados significativos, com destaque para a intervenção com 2 g de mio-inositol associado a 200 μ g de ácido fólico, que foi eficiente no controle do hormônio luteinizante e hormônio folículo estimulante. Assim, considerando 2 g de mio-inositol associado a 2 μ g de ácido fólico, as diferenças entre as médias foram: para o índice do modelo de avaliação da homeostase, MD = 1,4 ($p = 0,00$); para insulina, MD = 5,9 ($p = 0,00$); para o hormônio folículo estimulante, MD = 2,5 ($p = 0,00$); e para o hormônio luteinizante, MD = 4,9 ($p = 0,00$). A intervenção com 4 g de mio-inositol, com 400 μ g de ácido fólico, resultou na redução da glicemia sérica, com MD = 6,2 ($p = 0,00$). **Conclusão-** Os resultados desta metanálise apontam para o mio-inositol como opção de tratamento para a síndrome do ovário policístico, considerando a ausência de efeitos colaterais e eficácia semelhante ou superior à metformina.

PALAVRAS-CHAVE: Mio-inositol, Metformina, Síndrome do Ovário Policístico.

INTRODUCTION

Polycystic ovary syndrome (PCOS) is a complex disease related to endocrine and metabolic dysfunction (LAVEN *et al.*, 2002; FIGUROVÁ *et al.*, 2017). PCOS can originate from a set of genetic, metabolic and environmental factors (DUMESIC *et al.*, 2015), affecting mostly women between menarche and menopause, reaching a prevalence of 6 to 16% of women of childbearing age (ROSA-e-SILVA, 2018).

Women with PCOS may present reproductive, metabolic, psychological disorders, increased risk for cardiovascular diseases, dyslipidemia, visceral obesity, depression (FACCHINETTI *et al.*, 2019; DI SEGNI *et al.*, 2017), infertility (LEGRO *et al.*, 2013) and, very commonly, insulin resistance and hyperinsulinemia, which reaches 80% obese women and 30 to 40% of thin women with PCOS (NEHRA *et al.*, 2017).

Insulin resistance is a consequence of the excess of ovarian estrogens, which eventually affects the translation of the insulin signal, reducing the functionality of this signaling (COSTANTINO *et al.*, 2009). Insulin signaling can be affected by the deficiency or insufficiency of inositol phosphoglycans, which are insulin mediators (ROMERO; LARNER *et al.*, 1993).

The measurement of the degree of insulin resistance is performed by calculating

the index of the homeostasis assessment model (HOMA). Insulin resistance generates hyperinsulinemia that can alter follicle stimulating hormone (FSH) and luteinizing hormone (LH), impairing the selection of dominant ovarian follicle (ARTINI *et al.*, 2013; YANG *et al.*, 2018). Hyperinsulinemia can also alter sensitivity to LH, causing an increase in androgen production (NELSON *et al.*, 2001; ORTEGA-GONZALEZ *et al.*, 2005), directly interfering with fertility and altering the menstrual cycle. Insulin resistance may be a key factor in the pathogenesis of PCOS and the use of insulin sensitizers has been shown to be a viable treatment option. Two likely insulin sensitizers are metformin and myo-inositol (ANGIK *et al.*, 2015).

Inositol is a vitamin of the B complex and can be synthesized endogenously or consumed through the diet, through bran and seeds (BIZZARRI *et al.*, 2016). There are nine possible forms of steroid isomers, they are: scilo-, mucous-, epi, neo, allo-, cis-, D-chiro, L-chiro-inositol and myo-inositol. The isomers mio and d-chiro-inositol have the characteristic of insulin sensitizers. In addition to insulin sensitizer, myo-inositol improves ovulation, oocyte quality and reduces androgen levels, consequently improving the fertility parameter (NELSON *et al.*, 2001; ROSA-e-SILVA, 2018).

Metformin is an insulin sensitizer, commonly used for the treatment of type II diabetes, aids in weight loss and, when used in women with PCOS, may show improvements in menstruation and ovulatory cycle, with a reduction in serum androgens and body weight, however, the drug can cause gastrointestinal problems, such as nausea, poor appetite and diarrhea (SOARES-JUNIOR; DE SÁ, 2014), justifying the meta-analysis in question.

The purpose of this meta-analysis was to evaluate the efficiency of interventions with myo-inositol in PCOS, comparing it with metformin interventions, considering HOMA index, serum glucose and insulin levels and LH / FSH hormonal control as comparative parameters.

METHODS

It is a systematic review and meta-analysis, with an analytical and descriptive aspect. Consultations were held with the Health Sciences Descriptors (DeCS) and the Medical Subject Heading (MeSH), where the descriptors were identified: Myo-inositol, Metformin and Polycystic Ovary Syndrome. For the search for articles, the Boolean operators “AND”, “AND NOT” and “OR” were considered. Time limitation was not considered for systematic review and meta-analysis. However, for bibliographic review, articles published in the period from 1993 to 2020 were considered, giving preference to publications from the last 4 years, thus, considering the updated information. The articles were found in the databases: Scientific Electronic Library Online (SciELO), PubMed, on the National Center for Biotechnology Information (NCBI) website, using the identified descriptors.

In SciELO, 25 references were found and in PubMed, 453 references, all with

availability of the title, year, place of publication and summary. The repetitions and publications that were not related to the topic were excluded, resulting in 31 references, where 12 contributed data for systematic review and meta-analysis (Figure 1). The references obtained that constituted this sample were cataloged and analyzed.

Selection strategy

The selection was made through the analysis of abstracts and methods, considering the research protocol described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (MOHER *et al.*, 2009). The exclusion criteria were: master's dissertations, doctoral theses, articles that did not address the topic in a satisfactory way and research that did not adopt the randomized method. The following inclusion criteria were adopted: randomized research, research using the double-blind method, articles that discussed the relationship between the effect of myo-inositol and metformin, in the serum markers of insulin, glucose, LH and FSH, as well as the HOMA index. The adopted strategy allowed the selection of high quality research.




Figure 1. Flowchart: selection process of articles used in systematic review and meta-analysis.

Source: Source: Authors, (2021), adapted from Moher *et al.*, (2009).

Data synthesis and Analysis

After selecting the studies, according to the inclusion and exclusion criteria, data from the articles used in the meta-analysis were extracted and tabulated. Statistical analyzes were subdivided according to the administered concentrations of the drug metformin or myo-inositol supplement, considering the association with folic acid. Thus, being able to determine through the results in subgroups, which concentration was more effective in reducing the considered parameters. In this way, references from the total sample were segregated for data extraction, in order to demonstrate the efficiency of myo-inositol, comparing metformin results, in the treatment of PCOS. For this, the means of glucose, insulin, HOMA index, LH and FSH were compared, considering the difference between means before and after interventions. Some units of measurement conversions were performed, aiming at an assertiveness between the averages of the differences of the statistical tests. Statistical analyzes were performed with the aid of the STATA® 16.0 software, using the statistical test for continuous data mean difference, adopting the fixed and random effects, according to the heterogeneity between the data collected for each analysis.

Assessed hypotheses

Taking into account the antecedents, the present research had to evaluate the hypotheses: a) the supplement myo-inositol presents efficacy equal or superior to metformin for HOMA index and in the serum control of glucose and insulin; b) the myo-inositol supplement associated with folic acid is efficient in hormonal control (LH / FSH).

Determination of heterogeneity

To determine heterogeneity, the chi-square test of heterogeneity (c^2) and the Higgins and Thompson test (I^2) were used. Although the c^2 test determines significance or insignificance of heterogeneity, it has its efficiency compromised when the sample is small. On the other hand, the I^2 test shows assertive results when the sample is small. Thus, the association of the two tests, in determining heterogeneity, presents a greater chance of assertiveness, in the choice of the adopted effect. When the p-value is <0.05 , in the c^2 test, it is understood that the sample is heterogeneous, thus adopting the randomized effect. However, if the p-value is > 0.05 , the hypothesis is accepted that the sample does not have significant heterogeneity, considering the fixed effect. The I^2 test follows the same principle, however, it is evaluated according to the percentage presented: 0% without heterogeneity, 25% low heterogeneity, 50% moderate heterogeneity and 75% or more, high heterogeneity (HIGGINS; THOMPSON, 2002; HIGGINS *et al.*, 2003). For all statistical analyzes, a significance coefficient of 5% ($p < 0.05$) was considered for accepting the hypotheses.

RESULTS

The extracted data referenced the following analyzes: glucose for myo-inositol, five studies, resulting in 119 participants (n = 119); glucose for metformin, four searches (n = 107), insulin for myo-inositol, four searches (n = 81); insulin for metformin, seven searches (n = 187), HOMA index for myo-inositol, eight searches (n = 155); HOMA index for metformin, seven searches (n = 197), LH for myo-inositol, five searches (n = 105) and FSH for myo-inositol, four searches (n = 85) (Table 1).

Glucose: Data on treatment with myo-inositol (mg/dL)						
Author, Years	(N)	Ab ± SD	Aa ± SD	Age years	Research time	Administered concentration
(PKHALADZE et al., 2016)	20	83.60 ± 11.71	79.09 ± 10.09	15.95±1.85	3months	4g of myo-inositol and 400mg of folic acid
(NEHRA et al., 2017)	30	88.96 ± 2.79	82.00 ± 2.46	23.8± 0.69	6months	2g of myo-inositol
(DE LEO et al., 2013)	20	100.00 ± 1.40	95.00 ± 2.10	24 to 32	6months	3g of myo-inositol
(COSTANTINO et al., 2009)	23	87.60 ± 4.0	81.60 ± 4.0	18 to 40	3 to 4months	4g of myo-inositol and 400µg of folic acid
(SHOKRPOUR et al., 2019)	26	97.5±6.60	89.80±8.50	28.3 ± 4.9	3months	4g of myo-inositol and 400µg of folic acid
Combined	119					
Insulin: Myo-inositol treatment data (mU/mL)						
(GENAZZANI et al., 2008)	10	12.40±2.20	6.50±1.10	Not included	3months	2g of myo-inositol and 200µg of folic acid
(PKHALADZE et al., 2016)	20	8.50±6.70	5.20±3.04	15.95±1.85	3months	4g of myo-inositol and 400µg of folic acid
(ARTINI et al., 2013)	25	11.40±2.20	5.50±1.10	34.9±2.1	3months	2g of myo-inositol and 200µg of folic acid
(SHOKRPOUR et al., 2019)	26	13.00±3.40	10.80±3.00	28.3 ± 4.9	3months	4g of myo-inositol and 400µg of folic acid
Combined	81					
HOMA Index: Data on myo-inositol treatment						
(GENAZZANI et al., 2008)	10	2.8±0.6	1.4±0.3	not included	3months	2g of myo-inositol and 200µg of folic acid
(PKHALADZE et al., 2016)	20	1.81±1.38	1.03±0.64	15.95±1.85	3months	4g of myo-inositol and 400µg of folic acid
(ARTINI et al., 2013)	25	2.5±0.6	1.1±0.3	34.9±2.1	3months	2g of myo-inositol and 200µg of folic acid
(FRUZZETTI et al., 2017)	24	2.1±0.5	1.5±0.4	21.6±6.6		4g of myo-inositol and 400µg of folic acid
(SHOKRPOUR et al., 2019)	26	3.1±0.9	2.6±0.8	28.3 ± 4.9	3months	4g of myo-inositol and 400µg of folic acid
(DE LEO et al., 2013)	20	3.8±0.3	2.7±0.3	24 to 32	6months	3g of myo-inositol
(NEHRA et al., 2017)	30	4.18±0.41	2.88±0.27	23.8± 0.69	6months	2g of myo-inositol
Combined	155					

LH: Data regarding treatment with myo-inositol (mIU/mL)						
(ARTINI et al., 2013)	25	13.5±2.2	8.6±1.6	34.9±2.1	3months	2g of myo-inositol and 200µg of folic acid
(GENAZZANI et al., 2008)	10	14.5±2.2	9.6±1.6	Not included	3months	2g of myo-inositol and 200µg of folic acid
(PKHALADZE et al., 2016)	20	9.11±5.70	7.56±4.50	15.95± 1.85	3months	4g of myo-inositol and 400µg of folic acid
(DE LEO et al., 2013)	20	11.1±0.7	8.6±0.4	24 to 32	6months	3g of myo-inositol
(NEHRA et al., 2017)	30	12.62±1.62	11.28±1.44	23.8± 0.69	6months	2g of myo-inositol
Combined	105					
FSH: Data regarding treatment with myo-inositol (mIU/mL)						
(ARTINI et al., 2013)	25	5.5±0.5	3.0±0.3	34.9±2.1	3months	2g of myo-inositol and 200µg of folic acid
(GENAZZANI et al., 2008)	10	6.5±0.5	4.0±0.3	Not included	3months	2g of myo-inositol and 200µg of folic acid
(DE LEO et al., 2013)	20	5.5±0.2	6.1±0.3	24 to 32	6months	3g of myo-inositol
(NEHRA et al., 2017)	30	6.8±0.51	7.4±0.53	23.8± 0.69	6months	2g of myo-inositol
Combined	85					
Glucose: Metformin treatment data (mg/dL)						
(NEHRA et al., 2017)	30	88.93±2.41	82.76±2.18	23.26±1.03	6months	1500mg of metformin
(ZAHRA et al., 2016)	20	100.2±9.5	100.8±5.3	25.8 ± 6.1	3months	1500mg of metformin
(SHOKRPOUR et al., 2019)	27	97.00±7.60	94.80±9.70	27.7 ± 3.2	3months	1500mg of metformin
(ORTEGA-GONZALEZ et al., 2005)	30	94.7±3.0	91.0±2.5	28.6±0.7	6months	2550mg of metformin
Combined	107					
Insulin: Metformin treatment data (mU/mL)						
(NEHRA et al., 2017)	30	18.98±1.48	14.04±1.10	23.26± 1.03	6months	1500mg of metformin
(JAVANMANESH et al., 2015)	48	10.65±3.03	10.40±2.64	29.37±4.6	6months	1500mg of metformin
(SHOKRPOUR et al., 2019)	27	12.6±2.2	11.9±2.4	27.7 ± 3.2	3months	1700mg of metformin
(ZAHRA et al., 2016)	20	17.2±9.2	14.1±9.3	25.8 ± 6.1	3months	1500mg of metformin
(DE LEO et al., 2013)	20	15±0.7	10.9±0.6	24 to 32	6months	1700mg of metformin
(FIGUROVÁ et al., 2017)	12	18.63±11.68	6.26±11.27	27.6±4.96	6months	1700 a 2550mg of metformin
(ORTEGA-GONZALEZ et al., 2005)	30	31.1±1.6	18.9±4.0	28.6±0.7	6months	2550mg of metformin
Combined	187					
HOMA index: Metformin treatment data						
(FRUZZETTI et al., 2017)	22	2.4±0.3	2.0±0.3	22.3±6.0	6months	1500mg of metformin
(NEHRA et al., 2017)	30	4.38±0.43	2.99±0.29	23.26± 1.03	6months	1500mg of metformin
(SHOKRPOUR et al., 2019)	27	3.0±0.7	2.8±0.7	27.7 ± 3.2	6months	1500mg of metformin
(JAVANMANESH et al., 2015)	48	2.23±0.73	2.09±0.69	29.37±4.6	6months	1500mg of metformin
(ZAHRA et al., 2016)	20	4.2±2.3	3.5±2.3	25.8 ± 6.1	3months	1500mg of metformin
(DE LEO et al., 2013)	20	3.2±0.4	2.4±0.3	24 to 32	6months	1700mg of metformin

(ORTEGA-GONZALEZ et al., 2005)	30	7.31±0.57	4.41±1.0	28.6±0.7	6months	2550mg of metformin
Combined	197					

Legend: Average before the intervention (Ab), Average after the intervention (Aa), Standard Deviation (SD).

Table 1. Data extracted and considered for meta-analysis after systematic review

Source: Authors, (2021).

Statistical analyzes were carried out according to the concentrations of drugs used in the interventions, thus, it was possible to assess which one showed greater efficiency in reducing or controlling the analyzed substances.

For serum glucose level after intervention with metformin, two concentrations of the drug were assessed in this meta-analysis. The results regarding the intervention with 1,500 mg of metformin, were not statistically significant, however, the intervention with 2,550 mg, was effective in the reduction of serum glucose with MD = 3.70 (95% CI = 2.30-5.10; p <0.05), indicating a reduction of approximately 4 mg of glucose. Likewise, for serum insulin, the concentrations: 1,500 mg and 1,700 mg were not effective for serum hormone control, on the other hand, the 2,550 mg intervention showed statistically significant results, with MD = 12.20 (95% CI = 10.66-13.74; p <0.05). The HOMA index showed a reduction, after the interventions, with 1,700 mg and 2,550 mg of metformin, the results were MD = 0.80 and MD = 2.90, respectively (p <0.05) (Figure 2).




Figure 2. Glucose, Insulin and HOMA index: Comparison between treatments with metformin.
Source: Authors, (2021).

Myo-inositol showed efficiency in serum glucose reduction, interventions using 2 g and 3 g showed, respectively, an average reduction of 7 mg and 5 mg of glucose. The association of 4 g of myo-inositol, with 400 μ g of folic acid, resulted in MD = 6.25 (95% CI = 4.32-8.18, $p < 0.05$), that is, after intervention, the serum glucose reduction is on average 6 mg. Also, insulin concentrations were analyzed after the interventions, with 2 g of myo-inositol, associated with 200 μ g of folic acid, and 4 g of myo-inositol, associated with 400 μ g of folic acid, the interventions presented, respectively, MD = 5.9 and MD = 2.4 ($p < 0.05$), determining greater effectiveness of the intervention with 2 g of myo-inositol associated with 200 μ g of folic acid. The HOMA index decreased after all interventions with myo-inositol, with or without an association with folic acid. The intervention with 2 g of myo-inositol, associated with 200 μ g of folic acid, showed an average reduction of 1.4 in the HOMA index. Likewise, the concentrations 4 g of myo-inositol, associated with 400 μ g of folic acid, 2 g of myo-inositol and 3 g of myo-inositol, pointed, respectively, MD = 0.60; MD = 1.30; and MD = 1.10 ($p < 0.05$) (Figure 3).




Figure 3. Glucose, Insulin and HOMA index: Comparison between treatments with myo-inositol.

Source: Authors, (2021).

The hormones LH and FSH were also analyzed, considering the interventions used the concentrations: 2 g of myo-inositol, associated with 200 µg of folic acid; 4 g of myo-inositol, associated with 400 µg of folic acid; 3 g of myo-inositol; and 2 g of myo-inositol. According to the statistical analyzes, the intervention with 2 g of myo-inositol, associated with 200 µg of folic acid, showed greater efficacy, in hormonal control of LH and FSH, with MD = 4.90 and MD = 2, respectively, 50 (p <0.05). On the other hand, the concentrations of 2 g and 3 g of myo-inositol were effective only in controlling LH, with an increase in FSH after interventions. The intervention with 4 g of myo-inositol, associated with 400 µg of folic acid, did not present a significant result, with MD = 1.55 (95% CI = - 1.63-4.73, p > 0.05) (Figure 4).




Figure 4. LH and FSH: Comparison between treatments with myo-inositol.

Source: Authors, (2021).

DISCUSSION

The diagnosis of PCOS is based on the criteria established in the ESRHE / ASRM Rotterdam consensus in 2003. For the diagnosis of the syndrome, it is necessary to have two of the following three characteristics: oligo ovulation, hyperandrogenism and presence of ovarian cysts (FAUSER *et al.*, 2004). However, although hyperinsulinemia and insulin resistance are not diagnostic criteria, these two physiological changes are prevalent in women with PCOS, usually associated with the pathogenesis of the syndrome, determining the importance of treating insulin resistance and hyperinsulinemia, usually done with insulin sensitizers. After analyzing the effects of the myo-inositol and metformin sensitizers, it was possible to observe that both had beneficial effects, effective in the treatment of PCOS, with regard to the serum reduction of insulin, glucose and improvement of the HOMA index.

Velazquez *et al.*, (1994), initially evaluated metformin supplementation at a dose of 1,500 mg per day for six months in 26 obese patients, the reported results were: weight loss and reduced androgen levels, improvement in menstrual cycle induction and ovulation. Metformin works by reducing glucose absorption, increasing insulin sensitivity, increasing peripheral glucose uptake without producing direct implications for pancreatic insulin production. Myo-inositol has recently been used as an insulin sensitizer. Glucose

metabolism is controlled by enzymes activated by an inositol phosphoglycan molecule, so when there is an enzyme deficiency, the mechanism is consequently compromised. Nehra *et al.*, (2017), found improved insulin sensitivity, glucose tolerance and reduced glycemic stimulus after the administration of myo-inositol, in the same way, Genazzani *et al.*, (2008), showed improvement in glucose level after supplementation of myo-inositol.

Insulin is an important parameter to be observed in patients with PCOS. The maintenance of hyperinsulinemia causes several complications characteristic of this pathology, such as ovulation problem, reduced quality of oocytes, increased production of androgens, altered menstrual cycle and reduced fertility (ANGIK *et al.*, 2015). According to Fruzzetti *et al.*, (2017), both metformin and myo-inositol are effective, improving insulin sensitivity, weight loss and reducing metabolic disorders.

The HOMA index measures insulin resistance by calculating the glucose-to-insulin ratio. Insulin resistance is determined by the demand for insulin greater than normal for the performance of physiological processes, due to a defect in the binding of insulin with its receptors or failure in the transmission of the insulin signal, causing increased insulin excretion, characterizing compensatory hyperinsulinemia, and at the same time, serum glucose levels remain within the reference values (BREMER; MILLER, 2008).

The present meta-analysis showed ineffectiveness of metformin in the reduction of the HOMA index, serum reductions in insulin and glucose, when administered 1,500 mg, showing statistically significant results when administered 2,550 mg. The importance of these results is in the relationship between drug concentration and increased risk of side effects, since the concentration is directly related to the time of the drug in the body. On the other hand, myo-inositol, associated or not with folic acid, showed statistically significant results for all concentrations, with a reduction in the HOMA index, serum reductions in insulin and glucose. Thus, the use of myo-inositol has advantages, considering the absence of side effects.

The excess of androgen is an important characteristic in the clinical picture of PCOS, and, therefore, the regulation of these hormones is fundamental for an improvement in signs and symptoms. In the study by Artini *et al.*, (2013), the intervention with myo-inositol for 6 to 8 weeks had beneficial effects in the reduction of androgens, gonadotropin and serum lipid, reducing 66% of the total testosterone and reduction of androstenedione. The intervention with myo-inositol was also related to an improvement in hirsutism and regulation of the menstrual cycle (ARTINI *et al.*, 2013).

In this meta-analysis, serum LH and FSH levels were analyzed after the administration of myo-inositol. The results showed a reduction of LH in the interventions using the concentrations 2 g, 3 g and 2 g associated with 200 μ g of folic acid. On the other hand, myo-inositol without the association with folic acid was not efficient in reducing FSH, however, the administration of 2 g associated with 200 μ g of folic acid, was effective in reducing the mean FSH. About 55 to 77% of women with PCOS have a high LH / FSH ratio. One of the

roles of FSH is to promote the growth of ovarian follicles. When LH is increased and FSH is reduced, the antral follicles suffer premature growth arrest and the oocytes lose their quality, thus compromising fertility (KALRO; LOUCKS; BERGA, 2001). Thus, for the control of FSH, the association of myo-inositol with folic acid becomes essential.

Metformin and myo-inositol showed equal efficiency as insulin sensitizers, improved HOMA index and reduced hyperinsulinemia. However, the use of metformin can cause gastrointestinal problems such as nausea, lack of appetite and diarrhea, and its use should be suspended within 48 hours before surgical cases with a risk of developing metabolic acidosis, therefore, adherence to treatment is compromised, determining the importance of researching other methods of treatment of insulin resistance, as effective as. According to Lin *et al.* (2019), women with PCOS have the same eating habits as women without PCOS, despite the fact that women with the syndrome have a high body mass index (BMI). It was also found a low fiber intake and high sodium intake. Something to note is the risk of developing diabetes and cardiovascular disease in women with PCOS (LIN *et al.*, 2019).

Guidance on healthy eating together with the encouragement of physical activity is essential and recommended by the International Guideline, Based on Evidence for the Evaluation and Management of PCOS. The nutritionist professional must act to improve the clinical picture of PCOS, and the nutritional intervention must be based on the possibility of supplementation of myo-inositol, in the objective of losing 5 to 10% of the original weight for overweight and obese women (TEEDE *et al.*, 2019). Still according to El Hayek *et al.*, (2016), lifestyle modification is one of the first-line treatments.

CONCLUSION

The present meta-analysis found efficacy of metformin, when administered a higher dosage. On the other hand, myo-inositol was efficient in reducing the HOMA index and serum insulin and glucose levels, regardless of dosage. When associated with folic acid, myo-inositol had potential to reduce FSH and LH. The results of this research are very relevant in the decision-making of the nutritionist, however, research is necessary considering environmental and genetic factors, considering samples that statistically represent the population with PCOS.

REFERENCES

ANGIK R.; JAJOO SS.; HARIHARAN C.; CHIMOTE A. **A Comparative Study of Metabolic and Hormonal Effects of Myo-inositol Vs Metformin in Women With Polycystic Ovary Syndrome: a Randomized Controlled Trial.** *Int. J Reprod Contraception, Obstet Gynecol*, v.4, p.189–194, 2015.

ARTINI PG.; DI BERARDINO OM.; PAPINI F. *et al.* **Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.** *Gynecol. Endocrinol*, v.29, p.375–379, 2013.

BIZZARRI M.; FUSO A.; DINICOLA S. *et al.* **Pharmacodynamics and pharmacokinetics of inositol (s) in health and disease.** Expert Opin Drug Metab Toxicol, v.12, p.1181–1196, 2016.

BREMER AA.; MILLER WL. **The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance.** Fertil Steril, v.89, p.1039–1048, 2008.

COSTANTINO D.; MINOZZI G.; MINOZZI F.; GUARALDI C. **Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: A double-blind trial.** Eur. Rev. Med. Pharmacol. Sci, v.13, p.105–110, 2009.

DE LEO V.; MUSACCHIO MC.; CAPPELLI V. *et al.* **A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients.** J. Metab Syndr, v.2, n.2, p.1-5, 2013.

DI SEGNI C.; SILVESTRINI A.; FATO R. *et al.* **Plasmatic and Intracellular Markers of Oxidative Stress in Normal Weight and Obese Patients with Polycystic Ovary Syndrome.** Exp Clin Endocrinol Diabetes, v.125, p.506–513, 2017.

DUMESIC DA.; OBERFIELD SE.; STENER-VICTORIN E. *et al.* **Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome.** Endocr ver, v.36, p.487–525, 2015.

EL HAYEK S.; BITAR L.; HAMDAR LH. *et al.* **Poly Cystic Ovarian Syndrome: An updated overview.** Front Physiol, v.7, p.1–15, 2016.

FACCHINETTI F.; ORRÙ B.; GRANDI G. *et al.* **Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review.** Gynecol Endocrinol, p.1–10, 2019.

FAUSER BCJM.; TARLATZIS.; FAUSER. *et al.* **Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.** Hum Reprod, v.19, p.41–47, 2004.

FIGUROVÁ J.; DRAVECKÁ I.; PETRÍKOVÁ J. *et al.* **The effect of alfacalcidol and metformin on metabolic disturbances in women with polycystic ovary syndrome.** Horm Mol Biol Clin Investig, v.29, p. 85–91, 2017.

FRUZZETTI F.; PERINI D.; RUSSO M. *et al.* **Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).** Gynecol Endocrinol, v.33, p.39–42, 2017.

GENAZZANI AD.; LANZONI C.; RICCHIERI F.; JASONNI VM. **Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.** Gynecol Endocrinol, v.24, p.139–144, 2008.

HIGGINS JPT.; THOMPSON SG.; DEEKS JJ.; ALTMAN DG. **Measuring inconsistency in knowledgebases.** BMJ, v.327, p.557–560, 2003.

HIGGINS JPT.; THOMPSON SG. **Quantifying heterogeneity in a meta-analysis.** Stat Med, v.21, p.1539–1558, 2002.

JAVANMANESH F.; KASHANIAN M.; RAHIMI M.; SHEIKHANSARI N. **A comparison between the effects of metformin and N -acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome.** *Gynecol Endocrinol*, v.32, p.285–289, 2015.

KALRO BN.; LOUCKS TL.; BERGA SL. **Neuromodulation in polycystic ovary syndrome.** *Obstet Gynecol Clin North Am*, v.28, n.5, p.35–62, 2001.

LAVEN JSE. IMANI B. EIJKEMANS MJC. *et al.* **New approach to polycystic ovary syndrome and other forms of anovulatory infertility.** *Obstet Gynecol Surv*, v.57, p. 755–767, 2002.

LEGRO RS.; ARSLANIAN AS.; EHRMANN DA. *et al.* **Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline.** *Journal Clin. Endocrinol Metab*, v.98, p.4565–4592, 2013.

LIN AW.; KAZEMI M.; JARRETT BY. *et al.* **Dietary and physical activity behaviors in women with polycystic ovary syndrome per the new international evidence-based guideline.** *Nutrients*, v.11, p.1–15, 2019.

MOHER D.; LIBERATI A.; TETZLAFF J. *et al.* **Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.** *PLoS Med*, v.6, p.1–6, 2009.

NEHRA J.; KAUSHAL J.; SINGHAL SR.; GHALAUT VS. **A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women.** *Int. Journal Pharm. Sci. Res*, v.8, n.4, p.1664–1670, 2017.

NELSON VL.; QIN KN.; ROSENFELD RL. *et al.* **The biochemical basis for increased Testosterone production in theca cells propagated from patients with polycystic ovary syndrome.** *Journal Clin. Endocrinol Metab*, v.86, p.5925–5933, 2001.

ORTEGA-GONZÁLEZ C.; CARDOZA L.; COUTIÑO B. *et al.* **Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.** *Journal Endocrinol*, v.184, p.233–239, 2005.

PAPALEO E.; UNFER V.; BAILLARGEON JP. *et al.* **Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.** *Fertil. Steril*, v.91, p.1750–1754, 2009.

PKHALADZE L.; BARBAKADZE L.; KVASHILAVA N. **Myo-Inositol in the Treatment of Teenagers Affected by PCOS.** *Int. J. Endoc*, v.16, p.1–6, 2016.

ROMERO G.; LARNER J. **Insulin Mediators and the Mechanism of Insulin Action.** *Adv. Pharmacol*, v.24, n.8, p.21–50, 1993.

ROSA-E-SILVA AC. **Conceito, epidemiologia e fisiopatologia aplicada à prática clínica.** In: *Síndrome dos ovários policísticos.* São Paulo: Federação Brasileira das Associações de Ginecologia e Obstetrícia (Febrasgo). Cap. 1. p. 1-15, 2018.

SHOKRPOUR M.; FOROOZANFARD F.; AFSHAR-EBRAHIMI F. *et al.* **Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.** *Gynecol Endocrinol*, v.35, p.406–411, 2019.

SOARES JÚNIOR JM.; DE SÁ MFS.; BARACAT EC. **Resistência insulínica na síndrome dos ovários policísticos deve ser sempre tratada?** *Rev. Bras Ginecol and Obstet*, v.36, p.47–49, 2014.

TEEDE HJ.; MISSO ML.; COSTELLO MF. *et al.* **Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.** *Hum Reprod*, v.34, p.251–268, 2019.

VELAZQUEZ EM.; MENDOZA S.; HAMER T. *et al.* **Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.** *Metabolism*, v.43, n.94, p.647–654, 1994.

YANG PK.; HSU CY.; CHEN MJ. *et al.* **The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome.** *Journal Clin. Endocrinol Metab*, v.103, p.890–899, 2018.

ZAHRA M.; SHAH M.; ALI A. RAHIM R. **Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome.** *Horm Metab Res*, v.49, p.103–108, 2016.

ÍNDICE REMISSIVO

A

Alimentação escolar 1, 2, 6, 9, 10, 11, 12, 13, 14, 15, 117, 118, 123, 234

Amamentação 155, 156, 157, 159, 160, 163, 164, 165, 167, 174, 178, 203, 204, 205, 208, 209, 210, 211, 212, 213

Antioxidante 36, 41, 42, 58, 59, 64, 65, 91

Apresentação contemporânea 27

Aproveitamento 82, 83, 85, 86, 87, 89, 90, 91, 92, 93, 96

Arroz especiais 27, 28, 29, 32

Atletas 124, 126, 127, 128, 129, 130

B

Banco de leite humano 155, 156, 157, 158, 159, 160, 162, 163, 164, 165, 196

Biofortificação 1, 2, 3, 6, 7, 8, 9, 10, 11, 13, 14, 15

Biscoito funcional 58

Blogueiras 16, 17, 18, 26

C

Cardápios 2, 9, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 86, 108, 127, 133, 136

Composição nutricional 16, 17, 18, 19, 25, 26, 96, 135, 136, 140

Controle de custos 97, 99, 109

Criação gastronômica 27

Cuidado pré-natal 143

Custo 4, 8, 54, 56, 59, 90, 97, 99, 100, 104, 105, 106, 107, 108, 109

D

Deficiências nutricionais 1, 5, 12, 25, 122, 133, 139, 215

Desperdício de alimentos 82, 83, 84, 94, 107, 112, 114

Dietas 16, 17, 18, 25, 26, 126, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 194, 195, 201

Doenças crônicas 26, 43, 54, 55, 56, 122, 178, 180, 220, 231

E

Esclerose lateral 34, 35, 36, 37, 38, 40, 41, 42

Esporte 124, 129, 130, 131

G

Gestantes 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 158, 159, 194, 195, 196, 197, 198, 199, 200, 201

Gestão 15, 88, 93, 95, 97, 100, 101, 102, 103, 104, 105, 106, 108, 109, 110, 111, 112, 113, 114, 147, 151, 158

H

Hábitos alimentares 6, 12, 16, 38, 48, 56, 98, 116, 117, 118, 122, 123, 126, 131, 167, 168, 195, 199, 201, 230, 231

I

Insegurança alimentar 1, 4, 142, 143, 144, 145, 148, 149, 150, 151, 152, 153

M

Metformina 67

Método BLW 166, 168, 170, 171, 172, 173, 174, 175

Mio-inositol 67

Moda 25, 26, 30, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141

Mulheres 5, 17, 18, 20, 23, 24, 138, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 164, 192, 195, 196, 198, 213

N

Neurônio motor 34, 36, 42

Nutrição 1, 8, 10, 12, 25, 26, 30, 34, 35, 36, 38, 40, 41, 56, 57, 82, 86, 88, 93, 94, 96, 98, 109, 110, 111, 112, 113, 114, 116, 117, 118, 122, 123, 124, 125, 126, 127, 129, 130, 131, 136, 139, 140, 141, 155, 157, 158, 160, 161, 164, 165, 176, 177, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 204, 212, 213, 214, 215, 224, 226, 227, 228, 230, 232, 234, 235

Nutrição infantil 1, 10, 12, 164, 212

O

Obesidade 17, 54, 93, 111, 113, 128, 132, 133, 134, 135, 139, 140, 141, 143, 148, 157, 165, 166, 173, 175, 177, 178, 180, 181, 187, 188, 189, 190, 227, 228, 229, 230, 231, 232, 233, 234

P

Perda de peso 17, 18, 35, 37, 133, 134, 135, 136, 137, 138, 196

Produto regional 27

Q

Questionário online 43

R

Resíduos de vegetais 83

Resíduos industriais 58

Resíduos sólidos 83, 84, 88, 89, 94, 95, 107, 109, 110, 113, 114

Rotulagem 43, 45, 47, 48, 49, 52, 56, 57, 106

S

Sabor 29, 43, 49, 50, 51, 61, 62, 65, 121, 195, 198, 199

Segurança alimentar e nutricional 1, 2, 3, 12, 13, 118, 123, 143, 144, 152, 231

Serviços de alimentação 82, 83, 84, 89, 92, 97, 98, 100, 111, 112, 113, 114, 127, 158, 196

Síndrome do ovário policístico 67

Sobrepeso 26, 38, 54, 132, 133, 134, 146, 148, 171, 179, 187, 188, 189, 190, 203, 231

U

Ultraprocessados 43, 45, 46, 47, 49, 50, 54, 55, 56, 57, 116, 117, 119, 120, 121, 122, 179, 180

Uva 58, 59, 60, 63, 64, 65

Nutrição sob a Ótica Teórica e Prática 2

www.atenaeditora.com.br 

contato@atenaeditora.com.br 

[@atenaeditora](https://www.instagram.com/atenaeditora) 

www.facebook.com/atenaeditora.com.br 

Nutrição sob a Ótica Teórica e Prática 2

www.atenaeditora.com.br 

contato@atenaeditora.com.br 

[@atenaeditora](https://www.instagram.com/atenaeditora) 

www.facebook.com/atenaeditora.com.br 